成纤维细胞活化蛋白
医学
免疫组织化学
肾透明细胞癌
间质细胞
肾细胞癌
卡波扎尼布
癌症研究
酪氨酸激酶
临床意义
肿瘤科
阶段(地层学)
酪氨酸激酶抑制剂
内科学
病理
靶向治疗
清除单元格
细胞
癌
生物标志物
受体酪氨酸激酶
成纤维细胞
癌症
癌相关成纤维细胞
肾癌
解剖病理学
生存分析
肿瘤进展
细胞生长
存活率
作者
María Riaza Montes,Beatriz Suárez,Jon Danel Solano-Iturri,David Lecumberri-Castaños,Ane Miren Iturregui,Charles H. Lawrie,María Armesto,Caroline E. Nunes‐Xavier,Rafael Pulido,José I. López,J.C. Angulo,Gorka Larrinaga
标识
DOI:10.3390/ijms262211112
摘要
Despite advances in the management of advanced clear cell renal cell carcinoma (ccRCC), robust biomarkers for prognosis and therapeutic response prediction remain elusive. Fibroblast activation protein-α (FAP), a marker of activated cancer-associated fibroblasts (CAFs), has emerged as a potential indicator of tumor aggressiveness and resistance to systemic therapies in various solid tumors. This study evaluated the clinical relevance of stromal FAP expression in a cohort of 137 patients with advanced ccRCC and long-term follow-up. FAP immunohistochemistry (IHC) was performed on primary tumor specimens and correlated with key clinicopathological features, disease-free survival (DFS), overall survival (OS), and radiological response to first-line tyrosine kinase inhibitors (TKIs). A significantly higher percentage of FAP-positive CAFs was observed in primary tumors with high histological grade, extensive local invasion (pT3-4), and advanced clinical stage (NCCN stage III-IV). Stromal FAP expression was associated with shorter DFS and OS. Moreover, tumors lacking FAP expression were more likely to achieve complete response to TKI therapy as defined by RECIST criteria. These findings highlight the potential of FAP IHC as a prognostic and predictive tool in advanced ccRCC and support further clinical validation.
科研通智能强力驱动
Strongly Powered by AbleSci AI